骨科手术中未诊断的血糖异常常见且与30天结局相关
基于美国外科医师学会国家手术质量改进项目数据库(2021-2023年)的241,987例骨科手术分析显示,22%患者存在未诊断的糖尿病前期,4%符合未诊断糖尿病标准;未诊断糖尿病与30天任何并发症风险轻度升高相关,但未诊断血糖异常与30天再入院或再手术无独立关联。
要点
- 骨科手术患者中未诊断血糖异常常见:22%为糖尿病前期,4%为糖尿病。
- 未诊断糖尿病与30天任何并发症风险轻度升高相关(aOR 1.1)。
- 未诊断血糖异常与30天再入院或再手术无独立关联。
核心结论
- 骨科手术患者中未识别血糖异常常见,且与术后并发症相关。
- 选择性术前HbA1c评估和手术特异性目标可能改善围手术期风险分层。
研究设计与样本
- 基于美国外科医师学会国家手术质量改进项目数据库(2021-2023年)的大型数据库研究,纳入241,987例有术前HbA1c记录的骨科手术。
- 根据糖尿病诊断和HbA1c水平将患者分为八组:正常血糖、未诊断糖尿病前期、未诊断糖尿病、已诊断糖尿病且控制近正常、很好、好、差、很差。
- 使用多变量逻辑回归调整人口学、合并症和手术因素,分析未诊断血糖异常与30天再入院和再手术的关联,以及术前HbA1c与30天并发症风险的关系。
主要发现
- 22%(52,609/241,987)有术前HbA1c记录的患者存在未诊断糖尿病前期,4%(10,690/241,987)符合未诊断糖尿病标准。
- 最佳情况敏感性分析假设所有无HbA1c测量患者均无糖尿病且血糖正常,所有735,259例骨科手术中未诊断血糖异常最低比例为9%(63,299)。
- 调整混杂变量后,未诊断糖尿病前期和未诊断糖尿病与30天再入院(aOR 0.95 [95% CI 0.88-1.0],p=0.12;aOR 0.99 [95% CI 0.84-1.2],p=0.94)或再手术(aOR 0.94 [95% CI 0.85-1.0],p=0.25;aOR 0.99 [95% CI 0.84-1.2],p=0.94)风险升高无独立关联。
- 未诊断糖尿病患者30天任何并发症的调整OR升高(aOR 1.1 [95% CI 1.0-1.2],p=0.03);已诊断糖尿病患者随着HbA1c分层升高,调整OR分别为1.2、1.1、1.2、1.4和2.0(所有p≤0.009)。
- 手术层面分析显示一致趋势但幅度可变:全髋关节置换术30天任何并发症率从5%(1425/27,812)升至17%(49/294);铰链式全膝关节置换术并发症率最高达30%(203/675),翻修全膝关节置换术为22%(11/49);肩部手术和膝关节镜并发症率均低(<6%),随HbA1c变化极小。
关键数值与推荐
- 未诊断糖尿病前期:有术前HbA1c记录但无糖尿病诊断且HbA1c处于糖尿病前期范围。
- 未诊断糖尿病:有术前HbA1c记录但无糖尿病诊断且HbA1c达到糖尿病标准。
- 已诊断糖尿病按HbA1c水平分为控制近正常、很好、好、差和很差五层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given that patients undergoing orthopaedic surgery frequently share risk factors that are associated with metabolic syndrome, the patients orthopaedic surgeons treat may be especially likely to have undiagnosed dysglycemia. Although its broader impact is documented in other specialties, its specific prevalence and association with postoperative outcomes after orthopaedic procedures remains incompletely defined. Quantifying this hidden burden is important to developing individual risk profiles, refining perioperative decision-making, and establishing targeted preoperative medical management strategies for patients considering orthopaedic surgery. QUESTIONS/PURPOSES: In a large-database study, we asked: (1) In adults who underwent orthopaedic surgery, what proportion of patients had previously undiagnosed dysglycemia? (2) Was undiagnosed dysglycemia associated with increased odds of 30-day readmission and reoperation compared with patients with normoglycemia? (3) What was the relationship between preoperative HbA1c levels and the 30-day risk of complications in patients who underwent orthopaedic surgery? METHODS: Among the 2,990,063 procedures recorded in the American College of Surgeons National Surgical Quality Improvement Program database (2021-2023), 25% (735,259 of 2,990,063) were orthopaedic. After excluding 75% (2,254,804 of 2,990,063) of nonorthopaedic procedures and 16% (493,272 of 2,990,063) of orthopaedic procedures without documented preoperative HbA1c, 8% (241,987 of 2,990,063) of all procedures were analyzed. Patients were assigned to one of eight glycemic groups (normoglycemic, undiagnosed prediabetes, undiagnosed diabetes, or diagnosed diabetes with near-normal, very good, good, poor, and very poor glycemic control) based on diabetes diagnosis and HbA1c level. The study cohort included patients undergoing a range of procedures, primarily consisting of total joint arthroplasty, fracture fixation, and spine surgery. The mean ± SD patient age was 66 ± 12 years and 56% [134,741 of 241,987] of patients were female. To address the first research question, the percentage of patients with previously undiagnosed dysglycemia in each cohort was measured, supplemented by a best-case sensitivity analysis to provide a conservative estimate for the entire surgical population. The second and third research questions investigated the association of undiagnosed dysglycemia on 30-day odds of readmission and reoperation and the relationship between preoperative HbA1c and 30-day odds of complications, using multivariable logistic regression adjusted for demographic, comorbidity, and procedural factors. To illustrate variation across operations, the 30-day complication rate of patients across HbA1c strata was evaluated for the 10 most frequent primary Current Procedural Terminology-coded procedures. RESULTS: We found that 22% (52,609 of 241,987) of patients with a recorded preoperative HbA1c had undiagnosed prediabetes and 4% (10,690 of 241,987) of patients met the criteria for undiagnosed diabetes. In a best-case sensitivity analysis in which we assumed that all patients without an HbA1c measurement did not have diabetes and had normoglycemia, the smallest percentage of patients with previously undiagnosed dysglycemia would have been 9% (63,299) across all 735,259 patients who underwent orthopaedic surgery. After adjusting for potentially confounding variables, neither prediabetes nor diabetes was independently associated with increased odds of 30-day readmission (adjusted OR 0.95 [95% CI 0.88 to 1.0]; p = 0.12 and adjusted OR 0.99 [95% CI 0.84 to 1.2]; p = 0.94) or reoperation (adjusted OR 0.94 [95% CI 0.85 to 1.0]; p = 0.25 and adjusted OR 0.99 [95% CI 0.84 to 1.2]; p = 0.94) compared with patients with normoglycemia. The adjusted ORs for any 30-day complication were higher in patients with undiagnosed diabetes (adjusted OR 1.1 [95% CI 1.0 to 1.2]; p = 0.03) and increased across HbA1c strata in those with diagnosed diabetes (adjusted OR 1.2, 1.1, 1.2, 1.4, and 2.0; all p ≤ 0.009) compared with patients with normoglycemia. Procedure-level analyses showed consistent patterns with variable magnitude: 30-day rates of any complication in THA rose from 5% (1425 of 27,812) to 17% (49 of 294) across HbA1c strata, whereas 30-day complication rates peaked at 30% (203 of 675) in hinged TKA and at 22% (11 of 49) in revision TKA. On the other hand, 30-day complication rates in shoulder procedures and knee arthroscopy remained uniformly low (< 6%) with minimal variation by HbA1c. CONCLUSION: Unrecognized dysglycemia is common among patients undergoing orthopaedic surgery and is associated with postoperative morbidity. Selective preoperative HbA1c assessment and procedure-specific targets may improve perioperative risk stratification. Examining these effects in clinical studies with procedure-specific preoperative HbA1c screening to identify and appropriately treat patients at risk could help to further validate these findings. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Schaschinger T, Munzinger R, Niederegger T, et al. Is Undiagnosed Dysglycemia Common in Orthopaedic Surgery and Is it Associated With 30-day Outcomes? A Large-database Study. Clin Orthop Relat Res. 2026. PMID: 42961352. doi:10.1097/CORR.0000000000003962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。